Evidence map›Paper›PMID 41836510›Full record

ArticleResearch square2026

Cannabinoid actions on sensitized dural nociceptors in a non-surgical mouse model of migraine-like pain.

Yoshihiro Kitaoka, Kyle Whyland, Zhiwei Li, Kyotaro Koshika, Toru Yamamoto, Yatendra Mulpuri, Igor Spigelman

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Yoshihiro KitaokaUniversity of California, Los Angeles.
Kyle WhylandUniversity of California, Los Angeles.
Zhiwei LiUniversity of California, Los Angeles.
Kyotaro KoshikaTokyo Dental College.
Toru YamamotoNiigata University.
Yatendra MulpuriNew York University.
Igor SpigelmanUniversity of California, Los Angeles.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Peripherally-restricted non-addictive cannabinoids for cancer pain treatmentUG3NS128148 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CAHILL, CATHERINE M, SCHMIDT, BRIAN L · 2023 to 2023
$3.2M
Peripherally-restricted cannabinoids for cancer and chemotherapy-induced painR01CA196263 · NCI · NEW YORK UNIVERSITY · PI SCHMIDT, BRIAN L, SPIGELMAN, IGOR · 2016 to 2020
$2.6M
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NCI NIH HHS R01 CA196263NINDS NIH HHS UG3 NS128148
6 · The paper itself

Abstract

Background: Migraine is a debilitating neurological disorder affecting ~ 15% of the global population with greater prevalence in females. Cannabinoid 1 and 2 receptor (CB1R and CB2R) agonists alleviate migraine symptoms. However, central nervous system (CNS) side effects mediated by CB1Rs limit their widespread use. We developed peripherally restricted cannabinoids (PRCBs) which lack CNS side effects. Here we examine actions of a PRCB on behavioral and physiological parameters in a mouse migraine model. Methods: Female 4-week-old C57BL/6J mice were acclimated to measurements of head withdrawal threshold (HWT) responses to periorbital von Frey filaments. After several days of baseline testing, mice (under brief isoflurane anesthesia) were administered pH-6.0 or pH-7.4 saline (4.5μL) supradurally via a 33-gauge cannula through the skin and connective tissue by taking advantage of unfused cranial sutures at bregma, followed 3-days later, by responses to a mild (pH-7.0 saline) supradural stimulation. The CB1R/CB2R agonist PRCB, PrNMI (5μM), was co-applied with pH-6.0 saline with or without the peripherally-restricted selective CB1R antagonist, 18A (20μM) or the selective CB2R antagonist, SR144528 (20μM). The potent selective CB2R agonist RNB61 (5μM) was also co-applied. Patch clamp recordings were obtained in retrogradely-labeled dural trigeminal ganglion (dTG) neurons acutely isolated from mice treated 3-days earlier with supradural pH-7.4 or pH-6.0 saline and 4% fluorogold. Results: Supradural pH-6.0 (but not pH-7.4) treatment produced allodynia symptoms which recovered by 48-hrs but were renewed by pH-7.0 supradural treatment. Supradural co-administration of pH-6.0/PrNMI prevented both the initial and latent allodynia symptoms. Co-administration of pH-6.0/PrNMI with 18A, or SR144528, abolished the preventative effects of PrNMI. Co-administration of pH-6.0/RNB61 did not prevent the initial allodynia or latent sensitization. Co-administration of pH-7.0/PrNMI did not prevent latent hypersensitivity. All dTGs had Aδ- or C-type nociceptor characteristics. Acid-induced depolarizations were enhanced in dTGs from pH-6.0-treated mice. PrNMI (1μM) decreased acid-induced depolarizations in dTGs from pH-7.4- (but not pH-6.0)-treated mice. RNB61 (0.5μM) had no effect on acid-induced depolarizations in dTGs from either group. Conclusions: These findings indicate that PrNMI prevents acid-induced sensitization and allodynia by activating peripheral neuronal CB1Rs and non-neuronal CB2Rs. CB2R activation alone is insufficient, and once sensitized, combined CB1R/CB2R activation loses efficacy.

Indexed as

Acid-sensing ion channelCannabinoidDura materMigraineNociceptor sensitizationTrigeminal ganglion

Identifiers

PMID41836510
PMCPMC12980366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.